AAV-ULK1 gene therapy
AAV-ULK1 gene therapy has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Feb 6, 2026: “Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction”.
1 paper studies it1 findingUpdated
See all 1 papers on AAV-ULK1 gene therapy
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
- 1 lab in 1 country
- Funders: Beijing Municipal Natural Science Foundation and 4 more
- Animals1
What did studies of AAV-ULK1 gene therapy find?
1Studies of AAV-ULK1 gene therapy measured one outcome, heart failure with preserved ejection fraction.
Heart failure with preserved ejection fraction
downin mice1
1 study
Heart failure with preserved ejection fraction
downin mice1
AAV-ULK1 gene therapy decreases heart failure with preserved ejection fraction in mice with HFpEF.
“ULK1 overexpression via AAV-9 attenuated the HFpEF phenotype in mice.”
Animalsin mice with HFpEFheartmales
Cardiovascular research